세계 장질환 검사 시장은 2023년 39억 8,000만 달러로 평가되며, 예측 기간 동안 2029년까지 연평균 4.69%의 안정적인 성장을 보일 것으로 예상됩니다.
장질환은 주로 위와 장을 포함한 소화관에 영향을 미치는 질병군입니다. 이러한 질병은 일반적으로 박테리아, 바이러스, 기생충 등 다양한 병원균에 의해 발생하며 경미한 위장 불편감에서 심각한 증상까지 다양한 증상을 유발합니다. 장내 병원균은 보통 오염된 음식이나 물을 통해 섭취함으로써 감염됩니다. 또한, 비위생적인 생활습관으로 인해 사람에서 사람으로 전염되기도 하며, 경우에 따라서는 감염된 동물이나 그 환경과의 접촉을 통해 장 질환이 전염되기도 합니다. 장 질환의 중증도는 경증으로 자연 치유되는 것부터 중증으로 생명을 위협하는 것까지 다양합니다. 경우에 따라 장 질환은 탈수, 전해질 불균형, 극단적인 경우 장기부전 등의 합병증을 유발할 수도 있습니다. 장 질환의 유병 기간은 원인균에 따라 다릅니다. 며칠 만에 자연 치유되는 감염이 있는가 하면, 만성화되어 몇 주에서 몇 달 동안 지속되는 감염도 있습니다.
| 시장 개요 | |
|---|---|
| 예측 기간 | 2025-2029년 |
| 시장 규모 : 2023년 | 39억 8,000만 달러 |
| 시장 규모 : 2029년 | 52억 5,000만 달러 |
| CAGR : 2024-2029년 | 4.69% |
| 급성장 부문 | 세균성 장질환 부문 |
| 최대 시장 | 북미 |
진단 기술, 특히 분자진단 및 현장 진단 검사의 발전으로 민감도, 특이도 및 검사 속도가 향상되고 있습니다. 장 질환의 조기 진단과 조기 관리의 중요성에 대한 의료진과 일반 대중의 인식이 높아지면서 검사 보급이 확대되고 있습니다. 식품 안전 규제와 요건이 강화되면서 식품 유래 병원체 식별 및 확산 방지를 위한 검사의 필요성이 증가하고 있습니다. 특히 적시 진단이 중요한 외딴 지역이나 자원이 부족한 환경에서 신속한 현장 검사 솔루션에 대한 수요가 증가하고 있습니다. 새로운 장내 병원균의 출현과 전염병 및 대유행 가능성으로 인해 검사 및 감시 활동에 대한 투자가 증가하고 있습니다.
기술의 발전
식품 안전 규제 급증
공중 보건에 대한 우려의 증가
신종 병원체 및 변종
샘플의 취급 및 보관
멀티플렉스 분석법
Global Enteric Disease Testing Market was valued at USD 3.98 billion in 2023 and is anticipated to witness an steady growth in the forecast period with a CAGR of 4.69% through 2029. Enteric diseases are a group of illnesses that primarily affect the gastrointestinal tract, including the stomach and intestines. These diseases are typically caused by various pathogens, such as bacteria, viruses, and parasites, and they can lead to symptoms ranging from mild gastrointestinal discomfort to severe illness. Enteric pathogens are typically transmitted through ingestion, often via contaminated food or water. Person-to-person transmission can also occur through poor hygiene practices, and in some cases, enteric diseases may be transmitted through contact with infected animals or their environment. The severity of enteric diseases can range from mild and self-limiting to severe and life-threatening. In some cases, enteric diseases can lead to complications, such as dehydration, electrolyte imbalances, and, in extreme cases, organ failure. The duration of enteric diseases varies depending on the causative agent. Some infections may resolve on their own within a few days, while others can become chronic and persist for weeks or even months.
| Market Overview | |
|---|---|
| Forecast Period | 2025-2029 |
| Market Size 2023 | USD 3.98 Billion |
| Market Size 2029 | USD 5.25 Billion |
| CAGR 2024-2029 | 4.69% |
| Fastest Growing Segment | Bacterial Enteric Diseases Segment |
| Largest Market | North America |
Advances in diagnostic technologies, particularly in molecular diagnostics and point-of-care testing, have improved the sensitivity, specificity, and speed of enteric disease testing. Increasing awareness among healthcare providers and the public about the significance of early diagnosis and management of enteric diseases has driven testing uptake. Stricter food safety regulations and requirements have propelled the need for testing to identify and prevent the spread of foodborne pathogens. The demand for rapid and point-of-care testing solutions has been on the rise, especially in remote and resource-limited settings, where timely diagnosis is critical. The emergence of new enteric pathogens and the potential for epidemics or pandemics have driven investment in testing and surveillance efforts.
Key Market Drivers
Technological Advancements
Molecular techniques, such as Polymerase Chain Reaction (PCR) and real-time PCR, have revolutionized enteric disease testing. They enable the detection of specific DNA or RNA sequences of pathogens, offering high sensitivity and specificity. These methods allow for the identification of multiple pathogens in a single test, reducing the time required for diagnosis. Next-Generation Sequencing (NGS) technology has advanced the field by providing comprehensive genetic information about enteric pathogens. This has been particularly valuable for outbreak investigation, epidemiology, and understanding genetic variations in pathogens. Multiplex assays allow the simultaneous detection of multiple pathogens in a single test. They have significantly improved testing efficiency and reduce the number of samples required. Portable and easy-to-use Point-of-Care Testing (POCT) devices have been developed for enteric disease testing. These devices provide rapid results, making them suitable for use in remote or resource-limited settings.
Automation has streamlined the enteric disease testing process in clinical laboratories. Automated systems can handle sample processing, testing, and result reporting, reducing the risk of human error and increasing throughput. Advances in serological and immunoassay techniques, such as ELISA (Enzyme-Linked Immunosorbent Assay), have improved the detection of antibodies or antigens associated with enteric pathogens. These tests are essential for assessing previous exposure or vaccination status. The development of biosensors and nanotechnology has enabled the creation of highly sensitive and rapid diagnostic tools. These technologies can detect the presence of pathogens at very low concentrations. Microfluidic devices allow for the manipulation of small volumes of liquid, making them suitable for miniaturized and efficient testing platforms. They are particularly useful for point-of-care testing. AI and machine learning algorithms are being used to analyze test results and identify patterns in large datasets. This can aid in the interpretation of complex diagnostic information and provide insights into disease trends. Digital health platforms and telemedicine services are increasingly being used to transmit test results, allowing for remote consultation with healthcare providers and enhancing patient access to their diagnostic information.
Innovations in sample preservation and transportation technologies have extended the shelf life of samples and made it possible to transport them to testing facilities over longer distances. Technological advancements have allowed for the monitoring of environmental factors, such as water quality and food safety, which can impact the spread of enteric diseases. Genomic epidemiology combines genomics and epidemiology to track the spread of enteric pathogens, which is particularly valuable in understanding outbreaks and transmission patterns. Bioinformatics software and tools aid in the analysis and interpretation of genomic data, facilitating the identification of pathogen strains and genetic variations. This factor will help in the development of the Global Enteric Disease Testing Market.
Increasing Surge in Food Safety Regulations
Enteric diseases, often caused by bacterial, viral, or parasitic pathogens, can be transmitted through contaminated food and water. By testing food products for these pathogens, the risk of foodborne illnesses is reduced. Food safety regulations set by government agencies require food manufacturers and producers to meet specific standards for pathogen control. Compliance often involves routine testing for enteric pathogens to verify the safety of products. Rigorous food safety practices and testing contribute to consumer confidence in the safety of the food supply. Consumers are more likely to purchase and consume products from companies that adhere to food safety regulations. Food safety regulations aim to protect public health by minimizing the risk of foodborne outbreaks. Rapid detection and response to outbreaks are critical, and enteric disease testing helps identify the source of contamination.
Failure to comply with food safety regulations can lead to legal and financial consequences for food manufacturers and suppliers. To avoid liability, companies invest in testing to ensure their products meet safety standards. Many countries have stringent food safety regulations for imported food products. Compliance with these regulations is essential for companies engaged in international trade and export. Enteric disease testing helps meet these requirements. In the event of foodborne outbreaks or recalls, enteric disease testing is crucial for identifying the source of contamination. Rapid and accurate testing is necessary to prevent further distribution of contaminated products. Enteric disease testing extends beyond food products to environmental and facility monitoring. Testing surfaces, equipment, and production areas helps prevent cross-contamination.
By implementing enteric disease testing as part of their food safety programs, companies can proactively identify potential risks and take corrective actions to mitigate those risks. In addition to preventing foodborne illness, enteric disease testing supports quality assurance by ensuring the consistent quality of food products. The demand for food safety testing has driven innovation in testing methods, making them more sensitive, specific, and efficient. This innovation benefits both regulatory compliance and food safety. As the food supply chain becomes increasingly global, ensuring food safety is more complex. Enteric disease testing helps identify and control pathogens across international supply chains. This factor will pace up the demand of the Global Enteric Disease Testing Market.
Growing Public Health Concerns
Public health agencies and organizations continuously monitor and conduct surveillance of enteric diseases to detect outbreaks, track disease trends, and assess the impact of these diseases on the population. This data helps identify areas and populations at higher risk, prompting the need for testing. Early detection and containment of enteric disease outbreaks are critical to preventing widespread illness and transmission. Timely and accurate testing is essential in identifying and controlling outbreaks. Identifying individuals who may have been exposed to enteric pathogens is a key component of controlling the spread of these diseases. Testing is integral to contact tracing efforts, which are crucial in limiting further transmission. Public health authorities often promote vaccination against certain enteric diseases, such as typhoid and cholera. Testing may be used to determine vaccination status and the need for vaccination in specific populations. Public health officials assess the risk of enteric diseases in various settings, including healthcare facilities, schools, long-term care facilities, and communities. Testing helps identify and mitigate these risks.
Public health agencies monitor water and food safety to prevent the transmission of enteric diseases through contaminated water and food sources. Testing is a key component of this monitoring and risk reduction. Public health organizations run awareness and education campaigns to inform the public about enteric diseases, their symptoms, and prevention strategies. These campaigns often emphasize the importance of testing when symptoms are present. Public health concerns regarding the transmission of enteric diseases while traveling have prompted awareness and recommendations for travelers to seek testing before and after international trips. In the context of global health security, public health agencies and governments are vigilant about the potential spread of enteric pathogens. Rapid testing and response strategies are a part of preparedness and response plans.
When there is a suspected or confirmed case of an enteric disease, public health authorities conduct investigations to identify the source of infection and its potential impact on the community. Testing plays a central role in these investigations. Public health laboratories are involved in testing and monitoring efforts. These labs provide valuable data to epidemiologists and health officials to inform public health decisions. Public health concerns drive the allocation of resources to address enteric diseases, including funding for testing infrastructure and capacity building. Public health agencies are concerned with emergency preparedness for outbreaks, natural disasters, and bioterrorism events. Rapid testing is vital in these scenarios to ensure a prompt response. This factor will accelerate the demand of the Global Enteric Disease Testing Market.
Key Market Challenges
Emerging Pathogens and Variants
Emerging pathogens and their variants may have different genetic characteristics or unique virulence factors. Detecting and characterizing these variations can be challenging, as conventional testing methods may not effectively identify them. Traditional diagnostic tests, which are developed for known pathogens, may not perform well when applied to emerging or newly discovered pathogens. The accuracy of tests can be compromised if they are not designed to detect these novel pathogens. Emerging pathogens and variants can exhibit resistance to commonly used antibiotics, making accurate diagnosis even more critical. Failure to identify these pathogens can result in inappropriate treatment, contributing to the development of antimicrobial resistance. Emerging pathogens require close monitoring and surveillance to track their spread, prevalence, and genetic changes. Testing plays a crucial role in collecting data for epidemiological studies. Rapid identification and characterization of emerging pathogens are essential for controlling outbreaks and implementing effective public health measures to prevent further transmission.
Sample Handling and Storage
The risk of contamination during sample collection, handling, and storage is a primary concern. Even minor contamination can lead to false-positive or false-negative test results. Many enteric pathogens are sensitive to temperature. Inadequate temperature control during sample storage can lead to pathogen inactivation or overgrowth of contaminants, affecting the test results. Preserving the viability of enteric pathogens within the sample is essential for accurate testing. Preservation methods vary depending on the type of pathogen and the intended testing approach. Efficient logistics are required to ensure timely and appropriate transport of samples from the collection site to the testing facility. Delays or inadequate transportation can compromise the quality of samples. Depending on the type of testing, an adequate sample volume may be required. Collecting an insufficient volume can affect the sensitivity of the test and may necessitate recollection. Maintaining the proper storage conditions is crucial. For example, refrigeration is often needed to preserve the integrity of samples, but access to consistent refrigeration can be a challenge in some settings. Samples must be correctly labeled and identified to prevent mix-ups or confusion that could lead to erroneous test results. Over time, samples can degrade, leading to the loss of pathogen viability and making accurate testing impossible. Proper storage duration is essential to prevent sample degradation.
Key Market Trends
Multiplex Assays
Multiplex assays streamline the testing process by combining multiple tests into one, reducing the time and resources required for individual tests. Testing multiple targets in a single assay can provide faster results, which is crucial for timely diagnosis and patient management. Multiplex assays can detect a broad range of enteric pathogens, including bacteria, viruses, and parasites, in a single test. This comprehensive approach is valuable for diagnosing complex cases and outbreaks. Using a single sample for multiple tests reduces the need for additional specimen collection, preserving valuable samples for confirmatory or future testing. Laboratories can optimize their workforce by performing multiple tests in one run, leading to cost savings in terms of labor and resources. Multiplex assays contribute to resource efficiency, such as reduced consumption of reagents and consumables, making them more sustainable. The combination of multiple tests into one can enhance the overall accuracy and reliability of results. False negatives or positives can be minimized. Multiplex assays can be customized to detect specific combinations of pathogens, making them adaptable to local epidemiological needs.
Segmental Insights
Disease Type Insights
In 2023, the Global Enteric Disease Testing Market largest share was held by bacterial enteric diseases segment and is predicted to continue expanding over the coming years. Bacterial enteric diseases are widespread and can have significant public health implications. Diseases caused by bacteria like Salmonella, Escherichia coli (E. coli), and Campylobacter can result in outbreaks, severe illness, and even fatalities. This high prevalence and potential for severe outcomes make the testing for bacterial enteric diseases a top priority for healthcare systems. Many bacterial enteric diseases are foodborne illnesses, making them a focus of regulatory agencies, food safety organizations, and healthcare providers. Testing for these pathogens is crucial in identifying contaminated food sources and preventing outbreaks. Certain bacterial enteric diseases have epidemic potential, meaning they can quickly spread through communities or regions. Early and accurate detection is essential to control and manage outbreaks, which often garners significant attention and resources. Bacterial enteric disease testing has a long history of standardization and regulation. Many bacterial pathogens are well-established targets for diagnostic testing, and there are established protocols and methods in place for their detection. This standardization facilitates testing and regulatory approval. Bacterial enteric diseases can mimic the symptoms of other gastrointestinal conditions, making precise diagnosis vital for effective treatment. Clinicians rely on accurate diagnostic tests to guide patient care. Many countries have public health surveillance systems in place to monitor and report cases of bacterial enteric diseases. This surveillance relies on effective diagnostic testing to track the spread of infections and respond to outbreaks.
Regional Insights
The North America region dominates the Global Enteric Disease Testing Market in 2023. North America, particularly the United States and Canada, boasts highly developed healthcare infrastructure with advanced clinical laboratories and medical facilities. These facilities are well-equipped for comprehensive diagnostic testing, including enteric disease testing. The region is home to numerous leading healthcare and biotechnology companies, as well as prominent academic and research institutions. This fosters innovation in diagnostic technologies and methods for enteric disease testing. North America has stringent regulatory standards and quality control measures in place, ensuring that diagnostic tests meet high-quality and safety criteria. This encourages the development and adoption of reliable enteric disease testing methods. Both the United States and Canada have established public health programs and agencies dedicated to monitoring and controlling infectious diseases. These agencies often rely on advanced testing methods to carry out their surveillance and response efforts. North America experiences a notable burden of enteric diseases, including foodborne illnesses. This, coupled with the region's advanced healthcare system, creates a substantial demand for enteric disease testing.
Abbott Laboratories Ltd.
Beckton Dickinson & Co.
Biomerica Inc.
BIOMERIEUX SA
Bio-Rad Laboratories, Inc.
Cepheid
Coris BioConcept
DiaSorin S.p.A.
Meridian Bioscience Inc.
Quest Diagnostics Incorporated
In this report, the Global Enteric Disease Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
United States
Canada
Mexico
China
India
South Korea
Australia
Japan
Germany
France
United Kingdom
Spain
Italy
Brazil
Argentina
Colombia
South Africa
Saudi Arabia
UAE
Company Profiles: Detailed analysis of the major companies present in the Global Enteric Disease Testing Market.
Global Enteric Disease Testing Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Detailed analysis and profiling of additional market players (up to five).